1.42

0.70% -0.01

Pre-market: 1.39 -0.03 -2.11%

Inmune Bio Inc (INMB)

Overview News Price History Option Chain Financials Discussions Forecast

Inmune Bio Inc stock is traded at $1.42, with a volume of 418.21K. It is down -0.70% in the last 24 hours and down -2.07% over the past month. INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.

Previous Close:

$1.43

Open:

$1.39

24h Volume:

418.21K

Relative Volume:

1.07

Market Cap:

$37.75M

Revenue:

$50,000

Net Income/Loss:

$-41.60M

P/E Ratio:

-0.838

EPS:

-1.6946

Net Cash Flow:

$-20.20M

1W Performance:

+10.94%

1M Performance:

-2.07%

6M Performance:

-16.47%

1Y Performance:

-77.17%

1-Day Range:

$1.39

$1.50

1-Week Range:

$1.28

$1.50

52-Week Range:

$1.09

$11.64

Inmune Bio Inc Stock (INMB) Company Profile

Name

Inmune Bio Inc

Sector

Healthcare (1102)

Industry

Biotechnology (619)

Phone

(858) 964-3720

Address

225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA

Employee

Twitter

@INmuneBio

Next Earnings Date

2026-08-06

Latest SEC Filings

INMB's Discussions on Twitter

Compare INMB vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INMB Inmune Bio Inc	1.42	37.75M	50,000	-41.60M	-20.20M	-1.6946
VRTX Vertex Pharmaceuticals Inc	468.42	118.89B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	618.03	64.79B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	853.40	53.07B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	288.18	38.48B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	169.51	36.04B	742.00K	-1.37B	-1.07B	-7.0731

Inmune Bio Inc Stock (INMB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-01-25	Downgrade	BTIG Research	Buy → Neutral
Jul-01-25	Downgrade	Scotiabank	Sector Outperform → Sector Underperform
Jan-28-25	Initiated	Rodman & Renshaw	Buy
Oct-21-24	Initiated	Alliance Global Partners	Buy
Sep-27-24	Initiated	Raymond James	Outperform
Aug-22-24	Initiated	Scotiabank	Sector Outperform
Jun-01-23	Initiated	Robert W. Baird	Outperform
May-24-22	Downgrade	B. Riley Securities	Buy → Neutral
Jul-07-21	Reiterated	Maxim Group	Buy
Apr-21-21	Initiated	B. Riley Securities	Buy
Jan-22-21	Reiterated	Maxim Group	Buy
Sep-01-20	Initiated	BTIG Research	Buy
Jul-15-20	Reiterated	H.C. Wainwright	Buy

View All

Inmune Bio Inc Stock (INMB) Latest News

Jun 23, 2026

INmune Bio Advances Ebstrocel Toward UK Conditional Approval - TipRanks

Jun 23, 2026

MHRA backs INmune Bio (NASDAQ: INMB) plan for 2026 UK CORDStrom filing - Stock Titan

Jun 23, 2026

INMB Receives Regulatory Guidance for CORDStrom in Epidermolysis Bullosa - GuruFocus

Jun 23, 2026

INmune Bio receives MHRA alignment for RDEB therapy filing - Investing.com

Jun 23, 2026

INmune Bio receives MHRA alignment for RDEB therapy filing By Investing.com - Investing.com Canada

Jun 23, 2026

INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB - The Manila Times

Jun 23, 2026

INmune Bio wins MHRA backing for 2026 UK rare-disease filing - Stock Titan

Jun 23, 2026